Radt-02. Pre-Operative Versus Post-Operative Fractionated Stereotactic Radiotherapy: A Single-Institution Analysis Of 534 Resected Metastases
Haley Perlow,Sarah Hennings,Jared Bradshaw,Sohil Reddy,Sydney Luu,Jennifer Matsui,Brett Klamer,Khaled Dibs,Marshall Harrell,John McGregor,Russell Lonser,Daniel Prevedello,James Elder,Kyle Wu,Roshan Prabhu,Simeng Zhu,Raj Singh,Sasha Beyer,John Grecula,Dukagjin Blakaj,Evan Thomas,Raju Raval,Joshua Palmer
DOI: https://doi.org/10.1093/neuonc/noae165.0286
2024-11-29
Neuro-Oncology
Abstract:Patients with large or symptomatic brain metastases and limited intracranial disease typically have surgery followed by post-operative (post-op) stereotactic radiosurgery (SRS). However, SRS can lead to elevated rates of radiation necrosis (RN), meningeal disease (MD), and local failure (LF). Fractionated treatments can deliver a higher biological effective dose and may reduce the risk of LF, and pre-operative (pre-op) treatments may reduce the risk of RN and MD through treating smaller volumes and tumor sterilization. We hypothesize that pre-op fractionated stereotactic radiation therapy (FSRT) will reduce the incidence rate of RN, MD, and LF when compared to patients who receive post-op FSRT. A retrospective analysis was performed at a single institution and included patients who had surgical resection and radiation to at least one brain metastasis. Patients with multiple metastases resected, either during the same surgery or at different times in the disease course, were eligible for inclusion. Outcomes were evaluated on a per-lesion basis. The primary outcome was a composite endpoint defined by 1) LF, 2) MD, and/or 3) Grade 2 or higher (symptomatic) RN. 458 patients with 534 resected brain metastases were eligible for analysis. 235 metastases received pre-op FSRT, and 299 metastases received post-op FSRT. Overall, 15% of patients had multiple brain metastases resected. Overall, 6 (2.6%) pre-op and 13 (4.3%) post-op patients experienced LF. 21 (8.9%) pre-op and 38 (12.7%) post-op patients experienced symptomatic RN. 11 (4.7%) pre-op and 29 (9.7%) post-op patients were diagnosed with MD (p=0.031). 14% and 24% of metastases that received pre-op and post-op FSRT, respectively, experienced the composite endpoint (p=0.005). In our study, pre-op FSRT compares favorably to post-op FSRT primarily due to a 50% reduction in the incidence of MD. Differences in symptomatic RN or LF were small on adjusted analyses. Prospective validation of pre-op FSRT is needed.
oncology,clinical neurology